NK
Neil Kumar (Chief Executive Officer) filed 14 Form 4 reports in the trailing twelve months (0 purchases, 14 sales), most often in BridgeBio Pharma, Inc. (BBIO). The largest single filing was $6.0M of BBIO (80,000 sh across 8 lots, as filed), executed Apr 9. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
14
0 buys · 14 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$49.7M
shares × price, as filed
Last traded
Sep 17
Filed Sep 21
Median ADV $293.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $107.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
13 filings
Sector per market data · by filing · past 12 months
Most traded names
BBIORecent filings
BBIOSALE
BridgeBio Pharma, Inc.
View filing →
$1.3M25,728 sh × $48.81
Exec Aug 20 2025
Filed Aug 22 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $3.7M
80,000 sh across 8 lots
Exec Aug 7 2025
Filed Aug 11 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $3.3M
76,700 sh across 4 lots
Exec Jul 1 2025
Filed Jul 3 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $3.4M
100,756 sh across 2 lots
Exec May 19 2025
Filed May 20 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $2.6M
75,000 sh × $34.11
Exec Apr 22 2025
Filed Apr 24 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $2.8M
75,000 sh × $36.87
Exec Mar 25 2025
Filed Mar 27 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $2.5M
75,000 sh across 2 lots
Exec Feb 25 2025
Filed Feb 27 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $1.1M
31,467 sh × $36.14
Exec Feb 19 2025
Filed Feb 19 2025 · 5:30 PM ET More filings →